GLAXO.NS
GLAXO.NS
INE159A01016
GLAXOSMITHKLINE PHARMA LT
Loading chart...
Pure Price Volatility Risk (Market Swings)

The business itself is financially solid (Financial Health 90/100, minimal insolvency risk). The high overall score (7/7) is driven primarily by extreme stock price swings (±30.2% p.a.) and steep historical drawdowns.

Volatility Risk

Transparent evaluation of price volatility (SRI), Beta, and historical drawdowns.

Volatility Risk Score
7/7 Very High
7 / 7 SRI Price Fluctuation & Beta

Very high volatility or fundamental risks. Significant loss potential; strictly for aggressive investors. Moves noticeably less than the broader market (0.1x).

Beta (Market Relation)
0.08x
Defensive
Volatility (5Y p.a.)
30.2% p.a.
5-Year Horizon
Max Drawdown (5Y)
-39.3%
5-Year Horizon
Sharpe Ratio
0.30
Return / Risk
Speculative / High Risk: Score Basis:

Multi-Horizon Risk & Performance Matrix

Historical volatility, drawdowns, and risk-adjusted return across 1, 3, 5, and 10 years.

Volatility Expansion (3Y > 5Y) High Volatility
Timeframe
Volatility (p.a.)
Max Drawdown
Sharpe Ratio
Return (p.a.)
1 Year — — — -8%
3 Years 34.7% -39.3% 0.45 +18%
5 Years 30.2% -39.3% 0.3 +11.3%
10 Years 27.2% -39.3% 0.12 +5.7%

Automated Risk & Health Notes (Red Flags)

Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Elevated Short-Term Volatility: 3Y volatility (34.7%) is noticeably higher than the 5Y average (30.2%).
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (30.2% p.a.).
ende